|Description||MHY 908 is a dual PPARα/γ agonist and a melanogenesis inhibitor that suppresses mushroom tyrosinase activity (IC50 value 8.19 μM). MHY908 exhibits more potent activation of PPARα and PPARγ than fenofibrate and rosiglitazone, and enhances the binding and transcriptional activity of PPARα and -γ in AC2F cells. It reduces serum glucose, triglyceride, and insulin levels, however increases adiponectin levels without body weight gain.|
|Brife Description||PPARα/γ agonist, melanogenesis inhibitor|
|Synonyms||MHY908; MHY 908; MHY-908; 2-[4-(5-Chloro-2-benzothiazolyl)phenoxy]-2-methylpropanoic acid|
BMS-687453 is a potent and selective peroxisome proliferator activated receptor PPARα agonist. with an IC50 of 10 nM for human PPARalpha and approximately 410-f...
A potent PPARα modulator
GSK7227 is a novel class of PPARdelta partial agonists. It shows potent partial agonism of the PPARdelta target genes CPT1a and PDK4 in skeletal muscle cells.
Ciprofibrate is a peroxisome proliferator-activated receptor agonist.
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity as a drug for the treatment...
PT-S58 is a full peroxisome proliferator-activated receptor (PPAR) β/δ antagonist as a derivative of GSK0660. But PT-S58 has a three-fold higher affinity for th...
LY518674, a phenoxypropionic acid derivative, is a Potent and selective PPAR-alpha agonist produced a dose-dependent increase in serum HDL-c, resulting in 208 +...
FH535 sodium salt is a dual inhibitor of peroxisome proliferator-activated receptor (PPAR) and Wnt/β-catenin/TCF/LEF signaling. FH535 inhibits recruitment of th...